Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.
Since cyclosporin A (CsA) is an immunosuppressive agent, its beneficial effect in psoriasis suggests that immune cells may play a role in the pathogenesis and resolution of psoriasis. To determine early effects of CsA in psoriasis, we quantitated immune cells using double immunofluorescence microscopy on biopsy specimens obtained prior to therapy and after 3, 7, and 14 days of CsA therapy. CsA therapy resulted in significant reductions in the absolute number of immune cells (including T cells, monocytes/macrophages, and antigen presenting cells) contained within psoriatic skin. The effect was rapid, with over one-half of the reduction in the density of HLe1+ (human leukocyte antigen-1 positive or bone marrow derived) cells, including T cells, activated T cells, monocytes, and Langerhans cells (LCs), occurring within 3 days. Despite the overall reduction in the numbers of immunocytes in the skin, the proportion of T cells, Langerhans cells, and monocytes in relation to the total number of immune cells was unchanged with therapy, reflecting equally proportional losses of each subtype. Dermal CD1+DR+ cells (putative Langerhans cells), which are not found in normal skin but are present in lesional psoriasis skin, were virtually cleared from the papillary dermis after CsA therapy. Although absolute numbers of epidermal Langerhans cells, defined as cells expressing both CD1 (T6) and DR molecules (CD1+DR+), were also reduced after CsA, epidermal non-Langerhans CD1-DR+ cells (macrophages, activated T cells, DR- keratinocytes) demonstrated a proportionally greater decrease, with the ratio of CD1+DR+ Langerhans cells/non-Langerhans CD1-DR+ epidermal cells changing from a mean of 0.82 at baseline to 1.92 at day 14.(ABSTRACT TRUNCATED AT 250 WORDS)
Gupta
A K
AK
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109.
Baadsgaard
O
O
Ellis
C N
CN
Voorhees
J J
JJ
Cooper
K D
KD
D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D003524:Cyclosporins / Q000627:therapeutic use*; D004817:Epidermis / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007801:Langerhans Cells / Q000473:pathology*; D008214:Lymphocytes / Q000473:pathology*; D008264:Macrophages / Q000473:pathology*; D008875:Middle Aged; D010641:Phenotype; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D012867:Skin / Q000187:drug effects / Q000276:immunology* / Q000473:pathology
D000954:Antigens, Surface; D003524:Cyclosporins